S&P 500   3,785.38 (+2.91%)
DOW   30,261.78 (+2.61%)
QQQ   282.44 (+3.26%)
AAPL   145.22 (+1.94%)
MSFT   249.27 (+3.54%)
META   141.27 (+1.92%)
GOOGL   101.53 (+2.93%)
AMZN   122.63 (+5.82%)
TSLA   255.18 (+5.27%)
NVDA   131.31 (+4.95%)
NIO   16.72 (+7.94%)
BABA   84.59 (+5.15%)
AMD   68.58 (+3.74%)
T   16.07 (+1.07%)
MU   54.62 (+5.61%)
CGC   3.17 (+8.93%)
F   12.28 (+7.06%)
GE   67.06 (+5.44%)
DIS   101.15 (+4.14%)
AMC   7.30 (+6.10%)
PYPL   91.93 (+5.45%)
PFE   44.42 (+0.63%)
NFLX   240.69 (+0.69%)
S&P 500   3,785.38 (+2.91%)
DOW   30,261.78 (+2.61%)
QQQ   282.44 (+3.26%)
AAPL   145.22 (+1.94%)
MSFT   249.27 (+3.54%)
META   141.27 (+1.92%)
GOOGL   101.53 (+2.93%)
AMZN   122.63 (+5.82%)
TSLA   255.18 (+5.27%)
NVDA   131.31 (+4.95%)
NIO   16.72 (+7.94%)
BABA   84.59 (+5.15%)
AMD   68.58 (+3.74%)
T   16.07 (+1.07%)
MU   54.62 (+5.61%)
CGC   3.17 (+8.93%)
F   12.28 (+7.06%)
GE   67.06 (+5.44%)
DIS   101.15 (+4.14%)
AMC   7.30 (+6.10%)
PYPL   91.93 (+5.45%)
PFE   44.42 (+0.63%)
NFLX   240.69 (+0.69%)
S&P 500   3,785.38 (+2.91%)
DOW   30,261.78 (+2.61%)
QQQ   282.44 (+3.26%)
AAPL   145.22 (+1.94%)
MSFT   249.27 (+3.54%)
META   141.27 (+1.92%)
GOOGL   101.53 (+2.93%)
AMZN   122.63 (+5.82%)
TSLA   255.18 (+5.27%)
NVDA   131.31 (+4.95%)
NIO   16.72 (+7.94%)
BABA   84.59 (+5.15%)
AMD   68.58 (+3.74%)
T   16.07 (+1.07%)
MU   54.62 (+5.61%)
CGC   3.17 (+8.93%)
F   12.28 (+7.06%)
GE   67.06 (+5.44%)
DIS   101.15 (+4.14%)
AMC   7.30 (+6.10%)
PYPL   91.93 (+5.45%)
PFE   44.42 (+0.63%)
NFLX   240.69 (+0.69%)
S&P 500   3,785.38 (+2.91%)
DOW   30,261.78 (+2.61%)
QQQ   282.44 (+3.26%)
AAPL   145.22 (+1.94%)
MSFT   249.27 (+3.54%)
META   141.27 (+1.92%)
GOOGL   101.53 (+2.93%)
AMZN   122.63 (+5.82%)
TSLA   255.18 (+5.27%)
NVDA   131.31 (+4.95%)
NIO   16.72 (+7.94%)
BABA   84.59 (+5.15%)
AMD   68.58 (+3.74%)
T   16.07 (+1.07%)
MU   54.62 (+5.61%)
CGC   3.17 (+8.93%)
F   12.28 (+7.06%)
GE   67.06 (+5.44%)
DIS   101.15 (+4.14%)
AMC   7.30 (+6.10%)
PYPL   91.93 (+5.45%)
PFE   44.42 (+0.63%)
NFLX   240.69 (+0.69%)
NASDAQ:LGND

Ligand Pharmaceuticals - LGND SEC Filings & 10K Form

$91.24
+4.21 (+4.84%)
(As of 10/4/2022 11:19 AM ET)
Add
Compare
Today's Range
$90.10
$91.48
50-Day Range
$77.13
$107.56
52-Week Range
$72.57
$169.98
Volume
3,717 shs
Average Volume
149,613 shs
Market Capitalization
$1.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$177.00

Recent Ligand Pharmaceuticals SEC Filings

DateFilerForm TypeView
10/03/2022
8:20 AM
Ligand Pharmaceuticals (Subject)
Form 425
10/03/2022
8:18 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/30/2022
6:59 PM
Ligand Pharmaceuticals (Reporting)
OmniAb, Inc. (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
09/30/2022
4:13 PM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/30/2022
3:17 PM
Ligand Pharmaceuticals (Filer)
Form S-3ASR
09/22/2022
7:32 PM
HIGGINS JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4/A
09/16/2022
6:49 PM
HIGGINS JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/24/2022
4:21 PM
Avista Public Acquisition Corp. II (Subject)
Avista Public Acquisition Corp. II (Subject)
Ligand Pharmaceuticals (Filed by)
Form 425
08/09/2022
3:13 PM
Ligand Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/06/2022
7:00 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/06/2022
7:00 PM
HIGGINS JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/30/2022
5:32 PM
Haas Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/29/2022
6:33 PM
Haas Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
06/29/2022
4:17 PM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/21/2022
7:00 AM
Ligand Pharmaceuticals (Subject)
Form 425
06/21/2022
5:19 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/14/2022
4:55 PM
Berkman Charles S (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/14/2022
4:55 PM
FOEHR MATTHEW W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/14/2022
4:55 PM
HIGGINS JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/14/2022
4:54 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2022
5:47 PM
Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2022
5:47 PM
Boyce Sarah (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2022
5:47 PM
Cochran Jennifer R. (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2022
5:46 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2022
5:46 PM
Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2022
5:45 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2022
5:45 PM
LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2022
5:45 PM
Ligand Pharmaceuticals (Issuer)
Patel Sunil (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2022
7:44 AM
Ligand Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
05/13/2022
6:05 PM
FOEHR MATTHEW W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/10/2022
4:33 PM
HIGGINS JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2022
7:10 PM
Berkman Charles S (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2022
7:10 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2022
7:10 PM
FOEHR MATTHEW W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2022
7:09 PM
HIGGINS JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2022
3:08 PM
Ligand Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/05/2022
6:30 AM
Avista Public Acquisition Corp. II (Subject)
Avista Public Acquisition Corp. II (Subject)
Ligand Pharmaceuticals (Filed by)
Form 425
05/04/2022
3:03 PM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/22/2022
3:12 PM
Ligand Pharmaceuticals (Filer)
Form DEFA14A
04/22/2022
3:11 PM
Ligand Pharmaceuticals (Filer)
Form DEF 14A
07/21/2021
8:05 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/14/2021
7:19 PM
Cochran Jennifer R. (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/14/2021
5:15 PM
Cochran Jennifer R. (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
07/14/2021
3:08 PM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/08/2021
1:26 PM
Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/07/2021
8:39 PM
Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/07/2021
8:25 PM
Boyce Sarah (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/07/2021
8:25 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/07/2021
8:24 PM
Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/07/2021
8:24 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/07/2021
8:24 PM
LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/07/2021
8:23 PM
Ligand Pharmaceuticals (Issuer)
Patel Sunil (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/13/2021
7:57 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/23/2021
3:11 PM
Ligand Pharmaceuticals (Filer)
Form DEFA14A
02/23/2021
4:18 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2021
5:28 PM
Berkman Charles S (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2021
5:28 PM
FOEHR MATTHEW W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2021
5:27 PM
HIGGINS JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2021
5:27 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2021
4:30 PM
CARDINAL CAPITAL MANAGEMENT LLC /CT (Filed by)
Ligand Pharmaceuticals (Subject)
Form SC 13G/A
02/16/2021
8:34 AM
Ligand Pharmaceuticals (Subject)
STATE STREET CORP (Filed by)
Form SC 13G
02/12/2021
5:23 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/11/2021
3:42 PM
JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
Form SC 13G/A
02/11/2021
1:54 PM
Ligand Pharmaceuticals (Subject)
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (Filed by)
Form SC 13G/A
02/10/2021
10:14 AM
Ligand Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G/A
02/09/2021
5:08 PM
HIGGINS JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/09/2021
2:06 PM
Ligand Pharmaceuticals (Subject)
WASATCH ADVISORS INC (Filed by)
Form SC 13G
02/08/2021
4:19 PM
BANK OF AMERICA CORP /DE/ (Filed by)
Ligand Pharmaceuticals (Subject)
Form SC 13G/A
02/05/2021
4:03 PM
Berkman Charles S (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2021
4:03 PM
FOEHR MATTHEW W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2021
4:02 PM
HIGGINS JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2021
4:02 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/03/2021
6:45 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/28/2021
3:42 PM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/27/2021
6:04 PM
HIGGINS JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2021
6:03 PM
FOEHR MATTHEW W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2021
6:03 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2021
6:02 PM
Berkman Charles S (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2021
6:02 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2021
3:58 PM
Ligand Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
01/15/2021
3:11 PM
Ligand Pharmaceuticals (Filed by)
SEELOS THERAPEUTICS, INC. (Subject)
SEELOS THERAPEUTICS, INC. (Subject)
Form SC 13G/A
01/05/2021
7:30 PM
HIGGINS JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/21/2020
7:39 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/16/2020
3:19 PM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/10/2020
3:13 PM
Ligand Pharmaceuticals (Filer)
Form 8-K/A
12/09/2020
5:12 PM
HIGGINS JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/23/2020
7:32 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/10/2020
6:41 PM
HIGGINS JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/06/2020
3:11 PM
Ligand Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/04/2020
3:19 PM
Ligand Pharmaceuticals (Issuer)
Patel Sunil (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/30/2020
4:01 PM
Ligand Pharmaceuticals (Filer)
Form PRE 14A
10/30/2020
3:07 PM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/30/2020
7:03 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/20/2020
9:52 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/13/2020
7:44 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/09/2020
5:30 AM
Ligand Pharmaceuticals (Reporting)
Pfenex Inc. (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
10/08/2020
8:17 AM
Ligand Pharmaceuticals (Subject)
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (Filed by)
Form SC 13G/A
10/01/2020
7:42 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/30/2020
7:06 AM
Ligand Pharmaceuticals (Filed by)
Pfenex Inc. (Subject)
Form SC TO-T/A
09/23/2020
7:06 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
This page (NASDAQ:LGND) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.